Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.

Sanchis IM, Shukoor S, Irazabal MV, Madsen CD, Chebib FT, Hogan MC, El-Zoghby Z, Harris PC, Huston J, Brown RD, Torres VE.

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1151-1160. doi: 10.2215/CJN.14691218. Epub 2019 Jul 30.

PMID:
31362991
2.

Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.

Wang X, Constans MM, Chebib FT, Torres VE, Pellegrini L.

Am J Nephrol. 2019;49(6):487-493. doi: 10.1159/000500667. Epub 2019 May 22.

PMID:
31117065
3.

Subarachnoid Hemorrhage in Hospitalized Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease: A Nationwide Analysis.

Cheungpasitporn W, Thongprayoon C, Ungprasert P, Wijarnpreecha K, Kaewput W, Leeaphorn N, Bathini T, Chebib FT, Kröner PT.

J Clin Med. 2019 Apr 17;8(4). pii: E524. doi: 10.3390/jcm8040524.

4.

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE.

J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18.

PMID:
30228150
5.

Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

Chebib FT, Torres VE.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1765-1776. doi: 10.2215/CJN.03960318. Epub 2018 Jul 26. Review.

PMID:
30049849
6.

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):910.

7.

Outcomes of patients with autosomal-dominant polycystic kidney disease on peritoneal dialysis: A meta-analysis.

Boonpheng B, Thongprayoon C, Wijarnpreecha K, Medaura J, Chebib FT, Cheungpasitporn W.

Nephrology (Carlton). 2019 Jun;24(6):638-646. doi: 10.1111/nep.13431. Epub 2019 Apr 23.

PMID:
29952039
8.

The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.

Cornec-Le Gall E, Chebib FT, Madsen CD, Senum SR, Heyer CM, Lanpher BC, Patterson MC, Albright RC, Yu AS, Torres VE; HALT Progression of Polycystic Kidney Disease Group Investigators, Harris PC.

Am J Kidney Dis. 2018 Aug;72(2):302-308. doi: 10.1053/j.ajkd.2017.11.015. Epub 2018 Feb 1.

9.

Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies.

Chebib FT, Hogan MC, El-Zoghby ZM, Irazabal MV, Senum SR, Heyer CM, Madsen CD, Cornec-Le Gall E, Behfar A, Harris PC, Torres VE.

Kidney Int Rep. 2017 Jun 6;2(5):913-923. doi: 10.1016/j.ekir.2017.05.014. eCollection 2017 Sep.

10.

Generation and phenotypic characterization of Pde1a mutant mice.

Wang X, Yamada S, LaRiviere WB, Ye H, Bakeberg JL, Irazabal MV, Chebib FT, van Deursen J, Harris PC, Sussman CR, Behfar A, Ward CJ, Torres VE.

PLoS One. 2017 Jul 27;12(7):e0181087. doi: 10.1371/journal.pone.0181087. eCollection 2017.

11.

The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.

Ye H, Wang X, Constans MM, Sussman CR, Chebib FT, Irazabal MV, Young WF Jr, Harris PC, Kirschner LS, Torres VE.

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F677-F686. doi: 10.1152/ajprenal.00119.2017. Epub 2017 Jun 14.

12.

Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease.

Chebib FT, Harmon A, Irazabal Mira MV, Jung YS, Edwards ME, Hogan MC, Kamath PS, Torres VE, Nagorney DM.

J Am Coll Surg. 2016 Jul;223(1):118-126.e1. doi: 10.1016/j.jamcollsurg.2015.12.051. Epub 2016 Jan 14.

13.

Native Nephrectomy in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease.

Chebib FT, Prieto M, Jung Y, Irazabal MV, Kremers WK, Dean PG, Rea DJ, Cosio FG, Torres VE, El-Zoghby ZM.

Transplant Direct. 2015 Nov 1;1(10):e43. Epub 2015 Nov 18.

14.

Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.

Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, Torres VE, El-Zoghby ZM.

Nephrol Dial Transplant. 2016 Jun;31(6):952-60. doi: 10.1093/ndt/gfw008. Epub 2016 Feb 29.

15.

Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016.

Chebib FT, Torres VE.

Am J Kidney Dis. 2016 May;67(5):792-810. doi: 10.1053/j.ajkd.2015.07.037. Epub 2015 Oct 31. Review. No abstract available.

16.

Volume regression of native polycystic kidneys after renal transplantation.

Jung Y, Irazabal MV, Chebib FT, Harris PC, Dean PG, Prieto M, Cosio FG, El-Zoghby ZM, Torres VE.

Nephrol Dial Transplant. 2016 Jan;31(1):73-9. doi: 10.1093/ndt/gfv227. Epub 2015 Jun 4.

17.

Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.

Cheungpasitporn W, Chebib FT, Cornell LD, Brodin ML, Nasr SH, Schinstock CA, Stegall MD, Amer H.

Transplantation. 2015 Nov;99(11):2382-6. doi: 10.1097/TP.0000000000000750.

PMID:
25905984
18.

Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE.

Nat Rev Nephrol. 2015 Aug;11(8):451-64. doi: 10.1038/nrneph.2015.39. Epub 2015 Apr 14. Review.

19.

Interactions of mouse glycophorin A with the dRTA-related mutant G719D of the mouse Cl-/HCO3- exchanger Ae1.

Stewart AK, Chebib FT, Akbar SW, Salas MJ, Sonik RA, Shmukler BE, Alper SL.

Biochem Cell Biol. 2011 Apr;89(2):224-35. doi: 10.1139/o10-147.

PMID:
21455273

Supplemental Content

Loading ...
Support Center